Project Grant R50CA305237
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $187K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- The National Cancer Institute awarded Weill Medical College of Cornell University a $1,053,426 cooperative agreement on March 20, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to establish the AYA Cohort to Enhance Survivorship in NYC (ACES-NYC), a prospective cohort enrolling and following 2,000 adolescent and young adult cancer survivors treated at three New York City cancer centers—Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and Columbia...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Herbert Irving Comprehensive Cancer Center (HICCC) a $193,926 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2030. This award supports the development and implementation of investigator-led clinical trials within the NCI Clinical Trials Network (NCTN), Experimental Therapeutics Clinical Trials Network (ETCTN), and NCI Community...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $252,023 on September 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to adapt an evidence-based goals-of-care communication intervention for adolescent and young adult cancer patients (ages 15–39). The project addresses poor end-of-life outcomes in this population, including high rates of futile aggressive care interventions in the final month of life and low hospice enrollment. Current...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $140,364 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support the K99 phase of research developing cancer survivor hospitalization risk assessment through multimodal analysis of care manager–patient communications in managed long-term care settings. The project, "The CHAMP Study: Cancer Survivor Hospitalization Risk Assessment Through Multimodal Patient-Care...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $681,818 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research into restoring anti-tumor immunity in chromosomally unstable tumors. The research addresses chromosomal instability (CIN)—frequent chromosome missegregation during mitosis—as a genomic hallmark of solid tumors that correlates with immune evasion and resistance to immunotherapies. The project...
- The National Cancer Institute awarded Emory University $196,792 on August 6, 2026, under the Cancer Treatment Research program (CFDA 93.395) to expand and accelerate clinical trial research in pediatric central nervous system tumors through national clinical trials leadership and innovative trial development. Jason Fangusaro, MD, Professor of Pediatrics and Director of Developmental Therapeutics at Children's Healthcare of Atlanta and Emory University, leads the award. Over the five-year...
- The National Cancer Institute awarded the University of Rochester $814,967 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate trajectories of neurotoxicity among adolescents and young adults with Hodgkin lymphoma. The award funds research examining long-term neurotoxic effects of cancer therapy—including cancer-related cognitive impairment and peripheral and autonomic neuropathy—in this population despite the absence of central nervous...
- The National Cancer Institute awarded $269,597 to the Beckman Research Institute of The City of Hope on August 10, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and deliver clinical trials nursing education. The recipient will create a curriculum to train oncology clinical trials nurses in quality care for patients enrolled in cancer treatment trials, deliver the curriculum through five national in-person courses and virtual offerings to competitively selected...